Log in to your Inderes Free account to see all free content on this page.
Karolinska Development
1.19 SEK -0.83%1 investor is following this company
Karolinska Development is a Nordic investment company in the life science sector. The company focuses on identifying medical innovations to create and develop companies that further develop such innovations into differentiated products. Karolinska Development's portfolio consists of a number of companies focused on developing treatment methods for diseases that are classified as life-threatening and serious. The largest business operations are in the Nordic market.
Revenue
2.01M
EBIT %
-174.63 %
P/E
59.5
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
KDEV
Daily low / high price
1.17 / 1.228
SEK
Market cap
321.39M SEK
Turnover
245.91K SEK
Volume
203K
Financial calendar
Interim report
15.11.2024
Annual report
14.02.2025
Interim report
30.04.2025
General meeting
15.05.2025
Interim report
29.08.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
invoX Pharma Ltd | 47.7 % | 43.9 % |
Worldwide International Investments Ltd | 9.9 % | 9.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Karolinska Development’s portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01
Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio